Global Analgesics Market
Dublin, Sept. 16, 2022 (GLOBE NEWSWIRE) — The “Global Analgesics Market Size, Share & Industry Trends Analysis Report By Type, By Route of Administration, By Regional Outlook and Forecast, 2022 – 2028” report has been added to ResearchAndMarkets.com’s offering.
The Global Analgesics Market size is expected to reach $42.6 billion by 2028, rising at a market growth of 6.6% CAGR during the forecast period.
Analgesics, or painkillers, are drugs that are used to cure and relieve pain in the body. They are utilized when the suffering is extreme and the patient can no longer take it. Opioids, non-opioids, and compound analgesics (a mix of opioids and non-opioids) are the most often used topical analgesics worldwide. The most powerful painkillers are opioid medicines, which are developed from opium. They’re only available with a prescription and are usually utilized to treat moderate to severe pain. Non-opioid drugs, on the other hand, are made out of acetaminophen rather than opium. NSAIDs (non-steroidal anti-inflammatory medicines) are another class of treatments often used to relieve mild to moderate pain.
Increased rates of chronic diseases, such as tuberculosis, cardiovascular disorders, cancer, and arthritis are driving the expansion of the analgesics market. In addition, infectious disorders, such as respiratory, gastrointestinal, and neurological disorders are causing a significant increase in the number of patients.
As the prevalence of these disorders rises, so does the demand for painkillers, which is predicted to drive the analgesics market share even higher. Additionally, an increase in investment from commercial and government organizations for the production of drug manufacturing segments, as well as an increase in R&D activities for the innovation of analgesic goods, has boosted the growth of the analgesics market.
According to the World Health Organization, AIDS and malaria cost the lives of nearly 1.5 million people worldwide in 2020. Tuberculosis affects ten million people each year. Despite the fact that tuberculosis is a preventable and treatable infection, 1.5 million people die from it each year, making it the leading infectious killer on the planet. Analgesics, which primarily contain opioid medications, are also in high demand due to cardiovascular illnesses and cancer.
Furthermore, the analgesics market is expected to develop due to an increase in the number of clinical tests being conducted to assess the safety and efficacy of a vast variety of therapeutic medications. Furthermore, an increase in the elderly population, as well as cardiovascular disorders, cancer, and arthritis, is a crucial component driving analgesics market trends. The aging population also has more regular concerns with pain and aches, which helps the industry grow.
Furthermore, technical advancements in the pharma companies to create advanced analgesic pharmaceuticals are likely to provide lucrative prospects for the analgesic market in the coming years. Furthermore, the prevalence of major manufacturing businesses that manufacture and sell analgesic pharmaceuticals, rising demand for over-the-counter drugs, and rising healthcare spending all contribute to the market’s growth.
COVID-19 Impact Analysis
The COVID-19 pandemic had a severe impact on various economies all over the world. Numerous businesses across the world were significantly demolished by the effect of the pandemic. In addition, governments all over the world were compelled to impose lockdown in their nations in order to regulate the diffusion of the COVID-19 infection.
This lockdown scenario not only devastated various industries but also disrupted the worldwide supply chain of all the products and services. However, the healthcare sector observed a significant incline in the demand for its services during the COVID-19 outbreak. There was a substantial patient pool in hospitals amid the pandemic. Moreover, a considerable number of people suffered chronic pain in their chest as a result of the side effects of the virus.
Market Growth Factors
Rising incidences of chronic pain across the world
Physical pain is a prevalent problem all around the world. According to NCBI5, 20% of people all over the world suffer from some form of physical pain, with 10% of those identified with chronic pain for the first time each year. However, the issue of pain has been mostly considered as a medical problem, with public health paying little attention to it. The prevalence, frequency, and broad-ranging social and health consequences of pain mandate that the public health system pays particular attention to it. As a result, healthcare providers, as well as public health practitioners, is expected to have an increased understanding of pain along with the most effective public health as well as social policy solutions.
Rising demand for strong agonists
A pharmaceutical substance that activates certain brain receptors is known as an agonist. These agonists induce a robust physiological/pharmacological response even when just a limited number of receptors are activated, indicating that the medicine has high intrinsic activity. Strong agonist analgesics, including opioids, like encompass fentanyl, morphine, dihydromorphinone, oxycodone, and oxymorphone. The global health system was wrought havoc by COVID-19. During the pandemic, health organizations all over the world were aimed at regulating infection and addressing COVID-19 patients, which resulted in the suspension of elective surgeries and consultations, putting a strain on hospital and pain clinic pain services.
Market Restraining Factors
Risk of overdose and addiction
Due to the prevalence of deaths caused by drug overdose involving opioids and other analgesics remains high, researchers and governments around various countries continue to monitor opioid overdose deaths. Opioids caused about 50,000 deaths in 2019, more than six times the number of opioid-related fatal overdoses in 1999.
It’s crucial to determine and identify which substances are implicated in an overdose, how often they’re present, and how their presence changes over time. By recognizing drug involvement, practitioners can better identify effective prevention and response activities. Overdose death data has traditionally been analyzed using the National Vital Statistics System mortality data (NVSS-M), with the combined classifications of semi-synthetic, natural, and synthetic opioids
Key Topics Covered:
Chapter 1. Market Scope & Methodology
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Strategies deployed in Analgesics Market
Chapter 4. Global Analgesics Market by Type
4.1 Global Macro processing Market by Region
4.2 Global Micro processing Market by Region
Chapter 5. Global Analgesics Market by Route of Administration
5.1 Global Oral Market by Region
5.2 Global Transdermal Market by Region
5.3 Global Intravenous Market by Region
5.4 Global Topical Market by Region
5.5 Global Rectal Market by Region
Chapter 6. Global Analgesics Market by Region
Chapter 7. Company Profiles
7.1 AbbVie, Inc. (Allergan PLC)
7.1.1 Company Overview
7.1.2 Financial Analysis
7.1.3 Regional Analysis
7.1.4 Research & Development Expense
7.1.5 Recent strategies and developments:
7.1.5.1 Approvals and Trials:
7.2 Reckitt Benckiser Group PLC
7.2.1 Company Overview
7.2.2 Financial Analysis
7.2.3 Segmental and Regional Analysis
7.2.4 Research & Development Expenses
7.2.5 Recent strategies and developments:
7.2.5.1 Product Launches and Product Expansions:
7.3 Abbott Laboratories
7.3.1 Company Overview
7.3.2 Financial Analysis
7.3.3 Segmental and Regional Analysis
7.3.4 Research & Development Expense
7.3.5 Recent strategies and developments:
7.3.5.1 Product Launches and Product Expansions:
7.3.5.2 Approvals and Trials:
7.4 Johnson & Johnson
7.4.1 Company Overview
7.4.2 Financial Analysis
7.4.3 Segmental &Regional Analysis
7.4.4 Research & Development Expenses
7.5 Bayer AG
7.5.1 Company Overview
7.5.2 Financial Analysis
7.5.3 Segmental and Regional Analysis
7.5.4 Research & Development Expense
7.5.5 Recent strategies and developments:
7.5.5.1 Product Launches and Product Expansions:
7.6 Endo International PLC
7.6.1 Company Overview
7.6.2 Financial Analysis
7.6.3 Segmental and Regional Analysis
7.6.4 Research & Development Expense
7.7 GlaxoSmithKline PLC
7.7.1 Company Overview
7.7.2 Financial Analysis
7.7.3 Segmental and Regional Analysis
7.7.4 Research & Development Expense
7.7.5 Recent strategies and developments:
7.7.5.1 Partnerships, Collaborations, and Agreements:
7.7.5.2 Geographical Expansions:
7.8 Pfizer, Inc.
7.8.1 Company Overview
7.8.2 Financial Analysis
7.8.3 Regional & Segmental Analysis
7.8.4 Research & Development Expense
7.8.5 Recent strategies and developments:
7.8.5.1 Partnerships, Collaborations, and Agreements:
7.9 Sanofi S.A.
7.9.1 Company Overview
7.9.2 Financial Analysis
7.9.3 Segmental and Regional Analysis
7.9.4 Research & Development Expense
7.10. Eli Lilly And Company
7.10.1 Company Overview
7.10.2 Financial Analysis
7.10.3 Regional Analysis
7.10.4 Research & Development Expenses
7.10.5 Recent strategies and developments:
7.10.5.1 Partnerships, Collaborations, and Agreements:
7.10.5.2 Geographical Expansions:
For more information about this report visit https://www.researchandmarkets.com/r/lfl6li
Attachment
Global Analgesics Market
AT&T Inc. stock is trending on the Yahoo Finance Platform. Here is a visualization of $T performance over time, how that performance compares to the wider industry, and analyst projections for the current quarter.Check out the ticker page here.
Struggling Bed Bath & Beyond Inc. releases a list of dozens of stores it aims to close. Most of the stores on this list will close by the end of the month.
FedEx has blown three tires before the peak holiday shipping season, and chatter on the Street is that mighty Amazon may have played a role.
You can't guess the bottom. But a bargain is a bargain.
We’re getting toward the tail end of the year, and it’s time to start deciding just how to allocate the portfolio for a solid year-end return. In a recent note from JPMorgan, focused on the energy sector, 5-star analyst Arun Jayaram recommended oil and gas producers as likely to beat the overall markets going forward. Getting quickly to the bottom line, Jayaram states, "We remain fans of the longer-term story for natural gas driven by a growing global demand for low cost U.S. gas exports." With
The bank said a “deep recession” would be needed to bring down U.S. inflation.
If just two themes have defined the stock market in 2022, those themes would be stock splits and the bear market. Both have disproportionately affected the technology sector, with some of the largest tech companies in the U.S. opting for stock splits to reduce their high share prices, and the Nasdaq-100 tech index bearing the brunt of the broader market losses. Palo Alto Networks (NASDAQ: PANW), Shopify (NYSE: SHOP), and Tesla (NASDAQ: TSLA) have all conducted stock splits this year, and each stock has touched its 52-week low within the last four months.
NIO Inc. stock is trending on the Yahoo Finance Platform. Here is a visualization of $NIO performance over time, how that performance compares to the wider industry, and analyst projections for the current quarter.Check out the ticker page here.
As bad the news was for FedEx, it may be worse news for the U.S. economy — and an early sign of a recession.
Amazon's founder and executive chairman was the world's richest man for several years before falling to second place.
After three months of highly volatile trading, which have seen the S&P 500 drop down toward 3,600, rally up to 4,300, and fall back down to 3,900, investors can be forgiven for feeling some whiplash. The question that needs answering, however, is where will the markets go from here? Morgan Stanley strategist Andrew Slimmon believes that investors shouldn’t worry too much about the bear case. Worse-than-expected inflation numbers for August may have pushed the markets into a tumble this week, but
It's no secret that investors are worried about runaway inflation. Cathie Wood and Elon Musk see deflation as the bigger threat.
FedEx turned in poor earnings results and slashed its revenue forecast on Thursday as the company’s CEO warned that a “worldwide recession” is likely coming.
The stock market reached that point this past week. Oh, the market was hopeful, entering the week, that inflation had reached its peak, that the Federal Reserve would stop raising rates soon, that the bottom was in. All of this occurred the week before the Fed meets to discuss its next rate increase, which is likely to be another 0.75 percentage point.
Most stocks are having a lousy year in 2022. Here are a dozen that don't deserve being this deep in the red.
Wall Street is on a roller coaster again, as investors try to navigate the path between high inflation and the Fed’s aggressive interest rate hikes. What we know for certain is that the S&P 500 is down 18% year-to-date, and the NASDAQ is down 26%. At least one investing expert, however, is getting on his soapbox to encourage investors to buy now, while prices are low. This is the view of Shark Tank investor Kevin O’Leary. The venture capitalist makes a case for investors to take advantage of vol
There was a sell-off in cardboard packaging stocks this morning, with shares of International Paper (NYSE: IP) down 9.4% at 10:30 a.m. ET on Friday, Packaging Corporation of America (NYSE: PKG) shares down 9.7%, and the stock of WestRock (NYSE: WRK) down 9.8%. Shares of FedEx (NYSE: FDX) plunged more than 22% this morning after the company issued an earnings warning predicated on softening global volume. The volume FedEx referred to was the number of packages wrapped in cardboard and shipped to customers.
Of the 225 million Americans who are fully vaccinated, a mere 6,278 received Novavax. It's more popular in other countries like Japan and Australia, where it's used as a booster.
Pound sinks to lowest since 1985 as retail sales slump Germany seizes control of three Russian-owned Rosneft oil refineries FTSE 100 falls 0.6pc Ben Marlow: Shell must accept it has lost the battle on fossil fuels Sign up here for our daily business briefing newsletter
Yahoo Finance's Jared Blikre checks out the losses seen across market indices this week, while also looking at the U.S. dollar, sector losses, and transport stocks.
